SkinBioTherapeutics (SBTX) Share Price, News & Analysis

Company Overview

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.

Key Stats

• Today's Range: 19.50 to 20.17
• 50-Day Range: 14.98 to 20.75
• 52-Week Range: 7 to 21.50
• Volume: 1.15 million shs
• Average Volume: 660,269 shs
• Market Capitalization: £45.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SBTX Stock Analysis - Frequently Asked Questions

How have SBTX shares performed this year?

SkinBioTherapeutics' stock was trading at GBX 18.49 at the start of the year. Since then, SBTX shares have increased by 8.2% and is now trading at GBX 20.01.
View the best growth stocks for 2025 here.

How were SkinBioTherapeutics' earnings last quarter?

SkinBioTherapeutics plc (LON:SBTX) posted its quarterly earnings results on Wednesday, December, 4th. The company reported ($1.54) earnings per share (EPS) for the quarter. SkinBioTherapeutics had a negative trailing twelve-month return on equity of 115.86% and a negative net margin of 237.95%.

How do I buy shares of SkinBioTherapeutics?

Shares of SBTX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of SkinBioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SkinBioTherapeutics investors own include OptiBiotix Health (OPTI), Ecora Resources (ECOR), Avacta Group (AVCT), Inspired (INSE), Lb-shell (LBP), Anglo African Oil & Gas (AAOG) and Avino Silver & Gold Mines (ASM).

Company Calendar

• Last Earnings: 12/04/2024
• Today: 2/22/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:SBTX
• CUSIP: N/A
• CIK: N/A
• Web: www.skinbiotherapeutics.com
• Phone: +44-161-4682760
• Fax: N/A
• Employees: 11
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (1.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-3,714,060.24
• Net Margins: -237.95%
• Pretax Margin: N/A
• Return on Equity: -115.86%
• Return on Assets: -61.18%

Debt

• Debt-to-Equity Ratio: 27.57
• Current Ratio: 0.93
• Quick Ratio: 10.01

Sales & Book Value

• Annual Sales: £1.56 million
• Price / Sales: 29.28
• Cash Flow: GBX 2.22 per share
• Price / Cash Flow: 9.00
• Book Value: GBX 1.68 per share
• Price / Book: 11.92

Miscellaneous

• Outstanding Shares: 228,436,000
• Free Float: N/A
• Market Cap: £45.71 million
• Optionable: Not Optionable
• Beta: 2.01